<DOC>
	<DOCNO>NCT01078363</DOCNO>
	<brief_summary>Cardiac transplantation ultimate treatment option patient end stage heart failure . Cardiac allograft vasculopathy remain leading cause morbidity mortality transplantation . Angiotensin convert enzyme inhibitor use less one half transplant recipient . Preliminary data suggest angiotensin convert enzyme inhibitor retard atherosclerotic plaque development hallmark cardiac allograft vasculopathy . Moreover , class drug appear increase circulate endothelial progenitor cell number anti-inflammatory property , improve endothelial dysfunction , key precursor development cardiac allograft vasculopathy . The objective project investigate role angiotensin convert enzyme inhibitor , ramipril , prevent development cardiac allograft vasculopathy . During first month cardiac transplantation subject undergo coronary angiography intravascular ultrasound measurement plaque volume leave anterior descend coronary artery . Using coronary pressure wire , epicardial artery microvascular physiology assess . Finally , endothelial function mediator endothelial function , include circulate endothelial progenitor cell , measure . Subjects randomize double blind fashion either ramipril placebo . After 1 year , assessment repeat . The primary endpoint development cardiac allograft vasculopathy base intravascular ultrasound-derived parameter . The second aim ass effect ramipril endothelial dysfunction early transplantation . The final aim determine impact ramipril coronary physiology early transplantation .</brief_summary>
	<brief_title>Angiotensin Converting Enzyme ( ACE ) Inhibition Cardiac Allograft Vasculopathy</brief_title>
	<detailed_description>During first 4 year study , plan recruit patient within first month OHT . As become routine Stanford , study subject undergo baseline coronary angiography IVUS assessment leave anterior descend coronary artery . Coronary endothelial function assess well transmyocardial level ADMA mediator endothelial function . Blood sample obtain analyze circulate EPC number function . Epicardial microvascular coronary physiology leave anterior descend coronary artery determine measure FFR IMR coronary pressure wire ( adult ) . Subjects randomize either ACE I ( Ramipril ) , placebo , addition usual medication . During year 2 5 project , study subject undergo routine invasive assessment 1 year OHT . During 5th year project , data analysis manuscript preparation occur . Table 2 . Patient Flowchart Time post OHT Event 0-4 Weeks Recruitment enrollment 4-6 Weeks Baseline angiogram , endothelial function , coronary physiology IVUS study 4-6 ( time baseline ) Weeks Baseline blood sample circulate EPC study 4-6 Weeks Randomization ramipril placebo begin one week baseline study 5-7 Weeks Titration ramipril placebo Month 3 month 6 : blood sample EPC study . 11-13 Months 1 year angiogram , endothelial function , coronary physiology IVUS study 11-13 Months 1 year blood sample circulate EPC study The primary endpoint study change plaque volume determine IVUS analysis baseline 1 year later , treat ramipril compare treated placebo . Secondary endpoint include change circulate EPC number function , change ADMA level , change coronary endothelium-dependent vasodilation , change coronary physiology ( FFR IMR ) baseline 1 year . Although multiple potential mechanism ACE I might reduce CAV , evaluate beyond scope project . For reason , focus likely common final pathway endothelial dysfunction mediate dysregulation ADMA NOS , well change EPCs . If study show benefit ACE I therapy population , goal future study determine exact mechanism occur perform large , multicenter study compare ACE I placebo hard clinical endpoint . Study visit include two major time point 1 ) baseline angiogram IVUS include record angiographic data , lab data , clinical data . 2 ) assessment usual follow period post transplant , data point also collect research purpose . base line usually occur one month post transplant plus minus 2 week . F/u = q 2 week two month tx , per month six month TX , every two month patient 12 month TX . Each routine f/u visit include physical exam , vital sign , echocardiogram , chest x-ray , complete metabolic panel ( contain Creatinine ) , Complete blood count , immunosuppressant drug blood level , heart biopsy ( interval describe ) .</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<criteria>Heart transplant recipient within first month transplant ; 12 year age old ; Must serum creatinine less 2.0 mg/dl ; Will provide write informed consent ; Female patient childbearing potential must negative pregnancy test ; For pediatric patient , parent ( ) provide consent child sign assent . Less 12 year age ; Have one solid organ transplant time heart transplant ; Has serum creatinine great 2.0 mg/dl ; Pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Heart Transplantation</keyword>
</DOC>